DOCSLIB.ORG

Table 3: Average Gene Expression Profiles by Chromosome

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Table 3: Average Gene Expression Profiles by Chromosome Supplemental Data Table 1: Experimental Setup Correlation Array Reverse Fluor Array Extraction Coefficient Print Batch (Y/N) mean (range) DLD1-I.1 I A N DLD1-I.2 I B N 0.86 DLD1-I.3 I C N (0.79-0.90) DLD1-I.4 I C Y DLD1 DLD1-II.1 II D N DLD1-II.2 II E N 0.86 DLD1-II.3 II F N (0.74-0.94) DLD1-II.4 II F Y DLD1+3-II.1 II A N DLD1+3-II.2 II A N 0.85 DLD1 + 3 DLD1+3-II.3 II B N (0.64-0.95) DLD1+3-II.4 II B Y DLD1+7-I.1 I A N DLD1+7-I.2 I A N 0.79 DLD1 + 7 DLD1+7-I.3 I B N (0.68-0.90) DLD1+7-I.4 I B Y DLD1+13-I.1 I A N DLD1+13-I.2 I A N 0.88 DLD1 + 13 DLD1+13-I.3 I B N (0.84-0.91) DLD1+13-I.4 I B Y hTERT-HME-I.1 I A N hTERT-HME-I.2 I B N 0.85 hTERT-HME hTERT-HME-I.3 I C N (0.80-0.92) hTERT-HME-I.4 I C Y hTERT-HME+3-I.1 I A N hTERT-HME+3-I.2 I B N 0.84 hTERT-HME + 3 hTERT-HME+3-I.3 I C N (0.74-0.90) hTERT-HME+3-I.4 I C Y Supplemental Data Table 2: Average gene expression profiles by chromosome arm DLD1 hTERT-HME Ratio.7 Ratio.1 Ratio.3 Ratio.3 Chrom. Ratio.0 p.7vs0 p.13vs0 p.3vs0 Ratio.0 p.3vs0 vs0 3vs0 vs0 vs0 1p 1.00 1.04 0.0013 1.03 - 0.98 0.0293 1.00 1.02 - 1q 0.92 1.02 - 0.99 - 1.02 - 0.96 1.02 - 2p 1.03 1.05 - 1.00 - 1.00 - 1.01 0.96 0.0059 2q 0.95 1.02 - 1.01 - 0.99 - 0.99 1.01 - 3p 0.95 0.97 - 0.98 - 1.13 0.0009 0.96 1.22 <0.0001 3q 0.89 0.99 - 1.01 - 1.20 <0.0001 1.01 1.18 0.0010 4p 1.00 1.02 - 1.00 - 1.00 - 1.08 0.95 - 4q 1.05 0.96 - 0.97 - 0.97 - 1.12 0.97 - 5p 0.92 0.89 0.0411 0.98 - 1.01 - 0.89 1.05 - 5q 0.94 1.02 - 0.99 - 1.02 - 1.01 0.98 - 6p 0.88 1.08 0.0027 0.99 - 0.98 - 0.87 1.00 - 6q 1.02 1.01 - 1.06 - 1.00 - 1.06 0.91 0.0317 7p 0.95 1.14 <0.0001 0.98 - 1.00 - 0.95 1.00 - 7q 0.81 1.22 <0.0001 0.98 - 0.98 - 0.86 1.03 - 8p 0.88 1.07 0.0159 1.07 0.0063 1.04 - 1.04 0.99 - 8q 0.96 1.00 - 0.99 - 1.00 - 0.99 0.98 - 9p 1.05 1.01 - 1.02 - 0.95 - 1.10 1.01 - 9q 0.94 1.00 - 0.99 - 0.99 - 0.92 1.00 - 10p 0.90 1.04 - 1.02 - 1.04 0.0221 0.90 1.03 - 10q 1.05 1.00 - 0.98 - 0.98 - 1.08 1.01 - 11p 0.94 1.04 - 0.98 - 1.03 - 0.91 1.01 - 11q 0.92 1.00 - 0.96 - 0.98 - 0.97 0.98 - 12p 0.82 1.06 - 0.96 - 0.96 - 0.81 1.02 - 12q 0.96 1.04 0.0183 1.00 - 1.02 - 0.98 0.98 - 13q 0.99 1.01 - 1.26 0.0009 1.04 - 1.11 0.99 - 14q 0.92 1.02 - 1.01 - 1.02 - 0.93 1.00 - 15q 0.90 1.03 - 1.02 - 1.01 - 0.97 1.01 - 16p 0.93 1.05 - 0.99 - 0.97 - 0.85 1.00 - 16q 0.92 1.05 - 1.03 - 1.00 - 0.88 0.99 - 17p 1.07 1.08 - 1.00 - 0.98 - 1.05 0.98 - 17q 0.98 1.05 - 1.03 - 1.00 - 0.96 0.98 - 18p 1.03 0.96 - 1.02 - 0.97 - 1.02 0.96 - 18q 1.03 1.03 - 1.04 - 1.02 - 1.27 0.93 0.0483 19p 0.94 1.00 - 0.95 - 0.99 - 0.88 1.02 - 19q 0.93 1.03 - 0.95 - 0.98 - 0.98 1.01 - 20p 0.94 0.97 - 0.99 - 0.99 - 1.06 1.00 20q 0.84 1.02 - 1.02 - 0.99 - 0.88 1.00 21q 0.90 1.05 - 1.03 - 0.99 - 0.87 1.00 22q 0.94 1.04 - 0.98 - 0.97 - 0.91 1.00 Xp 0.89 0.97 0.0157 1.01 - 0.99 - 0.89 1.01 Xq 0.72 1.08 0.0265 0.98 - 0.98 - 0.82 1.03 Yq 1.30 0.93 - 0.99 - 0.69 <0.0001 0.97 0.96 For each chromosome arm, the average expression ratio for all genes on that arm relative to the reference RNA pool is given for the parental line (Ratio.0). The average chromosome arm expression ratios (relative to the same reference RNA for each chromosome transfer clone) are then normalized to the parental ratio value (Ratio.7vs0, Ratio.13vs0, Ratio.3vs.0) and their respective p-values from two-sample t-tests calculated. Ratio values having a p-value < 0.001 were considered significant and are in bold. P-values >0.05 are not reported. Supplemental Data Table 3: Genes significantly altered in expression in DLD1+7 a Upregulated genes Ratio.7vs0 Map Gene Description 12.40 7p21.2 TWIST twist homolog (acrocephalosyndactyly 3; Saethre-Chotzen syndrome) (Drosophila) 5.57 6p21.2 CDKN1A "cyclin-dependent kinase inhibitor 1A (p21, Cip1)" 5.16 6p21.2 CDKN1A "cyclin-dependent kinase inhibitor 1A (p21, Cip1)" 4.94 18 ESTs 4.89 Xq22.3 DSIPI "delta sleep inducing peptide, immunoreactor" 4.79 Incyte EST 4.78 4q13-q21 IL8 interleukin 8 4.68 15q26.1 IDH2 "isocitrate dehydrogenase 2 (NADP+), mitochondrial" 4.68 18q12.1 DSC2 desmocollin 2 3.99 12q13 NR4A1 "nuclear receptor subfamily 4, group A, member 1" 3.91 15q15 CKMT1 "creatine kinase, mitochondrial 1 (ubiquitous)" 3.82 22q13.1 LGALS1 "lectin, galactoside-binding, soluble, 1 (galectin 1)" 3.71 10p15-p14 AKR1C1 "aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1; 20-alpha (3-alpha)-hydroxysteroid dehydrogenase)" 3.71 1p22 CTBS "chitobiase, di-N-acetyl-" 3.55 1p33 TSPAN-1 tetraspan 1 3.55 12q22- PAH phenylalanine hydroxylase q24.2 3.46 15q23 TSPAN-3 tetraspan 3 3.45 Xq28 ZNF185 zinc finger protein 185 (LIM domain) 3.39 Xq11-q12 HEPH hephaestin 3.35 19q13.11 FXYD3 FXYD domain containing ion transport regulator 3 3.33 1 Human hbc647 mRNA sequence. 3.32 10q25 DUSP5 dual specificity phosphatase 5 3.30 5q31.2 KIAA0416 KIAA0416 protein 3.30 14q21-q22 PYGL "phosphorylase, glycogen; liver (Hers disease, glycogen storage disease type VI)" 3.26 7q21.3- NPTX2 neuronal pentraxin II q22.1 3.21 15q23 TSPAN-3 tetraspan 3 3.15 7q32.3 SMO smoothened homolog (Drosophila) 3.14 7q21 GNAI1 "guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1" 3.13 7q21.3- NPTX2 neuronal pentraxin II q22.1 3.12 1q25.2- PTGS2 prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase q25.3 and cyclooxygenase) 3.08 22q12.2 LIF leukemia inhibitory factor (cholinergic differentiation factor) 3.05 1pter- KIAA0237 KIAA0237 gene product p22.2 3.05 12p13.2- KLRC4 "killer cell lectin-like receptor subfamily C, member 4" p12.3 3.00 11p13 CD44 CD44 antigen (homing function and Indian blood group system) 2.98 7q22 TRIP6 thyroid hormone receptor interactor 6 2.97 6p25 SERPINB6 "serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 6" 2.97 19q13.32 FOSB FBJ murine osteosarcoma viral oncogene homolog B 2.93 7p12 GBAS glioblastoma amplified sequence 2.84 17p11.2 ALDH3A2 "aldehyde dehydrogenase 3 family, member A2" 2.84 8q24.13 C8FW phosphoprotein regulated by mitogenic pathways 2.83 5q12.1- SNK serum-inducible kinase q13.2 2.82 8p12-p11 DUSP4 dual specificity phosphatase 4 2.79 1q21 MCL1 myeloid cell leukemia sequence 1 (BCL2-related) 2.77 20q12 SDC4 "syndecan 4 (amphiglycan, ryudocan)" 2.77 17q22 ABCC3 "ATP-binding cassette, sub-family C (CFTR/MRP), member 3" 2.75 1q32.3 ATF3 activating transcription factor 3 2.74 2p21 CYP1B1 "cytochrome P450, family 1, subfamily B, polypeptide 1" 2.73 4p16 S100P S100 calcium binding protein P 2.69 7q36.1 RARRES2 retinoic acid receptor responder (tazarotene induced) 2 2.68 1p36.3 EGFL3 "EGF-like-domain, multiple 3" 2.67 10p15-p14 AKR1C4 "aldo-keto reductase family 1, member C4 (chlordecone reductase; 3-alpha hydroxysteroid dehydrogenase, type I; dihydrodiol dehydrogenase 4)" 2.63 2q32.1 SSFA2 sperm specific antigen 2 2.61 "trefoil factor 1 (breast cancer, estrogen-inducible sequence expressed in)" 2.61 15q13-q14 SGNE1 "secretory granule, neuroendocrine protein 1 (7B2 protein)" 2.59 16q13 MT1B metallothionein 1B (functional) 2.59 16q13 MT1E metallothionein 1E (functional) 2.56 7q22 PCOLCE procollagen C-endopeptidase enhancer 2.56 "Human DNA sequence from clone 742C19 on chromosome 22q12.3-13.1.
Load more

Recommended publications
  • Histone Isoform H2A1H Promotes Attainment of Distinct Physiological
    Bhattacharya et al. Epigenetics & Chromatin (2017) 10:48 DOI 10.1186/s13072-017-0155-z Epigenetics & Chromatin RESEARCH Open Access Histone isoform H2A1H promotes attainment of distinct physiological states by altering chromatin dynamics Saikat Bhattacharya1,4,6, Divya Reddy1,4, Vinod Jani5†, Nikhil Gadewal3†, Sanket Shah1,4, Raja Reddy2,4, Kakoli Bose2,4, Uddhavesh Sonavane5, Rajendra Joshi5 and Sanjay Gupta1,4* Abstract Background: The distinct functional efects of the replication-dependent histone H2A isoforms have been dem- onstrated; however, the mechanistic basis of the non-redundancy remains unclear. Here, we have investigated the specifc functional contribution of the histone H2A isoform H2A1H, which difers from another isoform H2A2A3 in the identity of only three amino acids. Results: H2A1H exhibits varied expression levels in diferent normal tissues and human cancer cell lines (H2A1C in humans). It also promotes cell proliferation in a context-dependent manner when exogenously overexpressed. To uncover the molecular basis of the non-redundancy, equilibrium unfolding of recombinant H2A1H-H2B dimer was performed. We found that the M51L alteration at the H2A–H2B dimer interface decreases the temperature of melting of H2A1H-H2B by ~ 3 °C as compared to the H2A2A3-H2B dimer. This diference in the dimer stability is also refected in the chromatin dynamics as H2A1H-containing nucleosomes are more stable owing to M51L and K99R substitu- tions. Molecular dynamic simulations suggest that these substitutions increase the number of hydrogen bonds and hydrophobic interactions of H2A1H, enabling it to form more stable nucleosomes. Conclusion: We show that the M51L and K99R substitutions, besides altering the stability of histone–histone and histone–DNA complexes, have the most prominent efect on cell proliferation, suggesting that the nucleosome sta- bility is intimately linked with the physiological efects observed.
    [Show full text]
  • Environmental Influences on Endothelial Gene Expression
    ENDOTHELIAL CELL GENE EXPRESSION John Matthew Jeff Herbert Supervisors: Prof. Roy Bicknell and Dr. Victoria Heath PhD thesis University of Birmingham August 2012 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. ABSTRACT Tumour angiogenesis is a vital process in the pathology of tumour development and metastasis. Targeting markers of tumour endothelium provide a means of targeted destruction of a tumours oxygen and nutrient supply via destruction of tumour vasculature, which in turn ultimately leads to beneficial consequences to patients. Although current anti -angiogenic and vascular targeting strategies help patients, more potently in combination with chemo therapy, there is still a need for more tumour endothelial marker discoveries as current treatments have cardiovascular and other side effects. For the first time, the analyses of in-vivo biotinylation of an embryonic system is performed to obtain putative vascular targets. Also for the first time, deep sequencing is applied to freshly isolated tumour and normal endothelial cells from lung, colon and bladder tissues for the identification of pan-vascular-targets. Integration of the proteomic, deep sequencing, public cDNA libraries and microarrays, delivers 5,892 putative vascular targets to the science community.
    [Show full text]
  • Differences for Ectopic Versus Eutopic Cells
    556 RBMO VOLUME 39 ISSUE 4 2019 ARTICLE Chemosensitivity and chemoresistance in endometriosis – differences for ectopic versus eutopic cells BIOGRAPHY Andres Salumets is Professor of Reproductive Medicine at the University of Tartu, and Scientific Head at the Competence Centre on Health Technologies, Tartu, Estonia. He has been involved in assisted reproduction for 20 years, first as an embryologist and later as a researcher. His major interests are endometriosis, endometrial biology and implantation. Darja Lavogina1,2,*, Külli Samuel1, Arina Lavrits1,3, Alvin Meltsov1, Deniss Sõritsa1,4,5, Ülle Kadastik6, Maire Peters1,4, Ago Rinken2, Andres Salumets1,4,7, 8 KEY MESSAGE Akt/PKB inhibitor GSK690693, CK2 inhibitor ARC-775, MAPK pathway inhibitor sorafenib, proteasome inhibitor bortezomib, and microtubule-depolymerizing toxin MMAE showed higher cytotoxicity in eutopic cells. In contrast, 10 µmol/l of the anthracycline toxin doxorubicin caused cellular death in ectopic cells more effectively than in eutopic cells, underlining the potential of doxorubicin in endometriosis research. ABSTRACT Research question: Endometriosis is a common gynaecological disease defined by the presence of endometrium-like tissue outside the uterus. This complex disease, often accompanied by severe pain and infertility, causes a significant medical and socioeconomic burden; hence, novel strategies are being sought for the treatment of endometriosis. Here, we set out to explore the cytotoxic effects of a panel of compounds to find toxins with different efficiency in eutopic versus ectopic cells, thus highlighting alterations in the corresponding molecular pathways. Design: The effect on cellular viability of 14 compounds was established in a cohort of paired eutopic and ectopic endometrial stromal cell samples from 11 patients.
    [Show full text]
  • Download Download
    Supplementary Figure S1. Results of flow cytometry analysis, performed to estimate CD34 positivity, after immunomagnetic separation in two different experiments. As monoclonal antibody for labeling the sample, the fluorescein isothiocyanate (FITC)- conjugated mouse anti-human CD34 MoAb (Mylteni) was used. Briefly, cell samples were incubated in the presence of the indicated MoAbs, at the proper dilution, in PBS containing 5% FCS and 1% Fc receptor (FcR) blocking reagent (Miltenyi) for 30 min at 4 C. Cells were then washed twice, resuspended with PBS and analyzed by a Coulter Epics XL (Coulter Electronics Inc., Hialeah, FL, USA) flow cytometer. only use Non-commercial 1 Supplementary Table S1. Complete list of the datasets used in this study and their sources. GEO Total samples Geo selected GEO accession of used Platform Reference series in series samples samples GSM142565 GSM142566 GSM142567 GSM142568 GSE6146 HG-U133A 14 8 - GSM142569 GSM142571 GSM142572 GSM142574 GSM51391 GSM51392 GSE2666 HG-U133A 36 4 1 GSM51393 GSM51394 only GSM321583 GSE12803 HG-U133A 20 3 GSM321584 2 GSM321585 use Promyelocytes_1 Promyelocytes_2 Promyelocytes_3 Promyelocytes_4 HG-U133A 8 8 3 GSE64282 Promyelocytes_5 Promyelocytes_6 Promyelocytes_7 Promyelocytes_8 Non-commercial 2 Supplementary Table S2. Chromosomal regions up-regulated in CD34+ samples as identified by the LAP procedure with the two-class statistics coded in the PREDA R package and an FDR threshold of 0.5. Functional enrichment analysis has been performed using DAVID (http://david.abcc.ncifcrf.gov/)
    [Show full text]
  • Genetic and Genomic Analysis of Hyperlipidemia, Obesity and Diabetes Using (C57BL/6J × TALLYHO/Jngj) F2 Mice
    University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Nutrition Publications and Other Works Nutrition 12-19-2010 Genetic and genomic analysis of hyperlipidemia, obesity and diabetes using (C57BL/6J × TALLYHO/JngJ) F2 mice Taryn P. Stewart Marshall University Hyoung Y. Kim University of Tennessee - Knoxville, [email protected] Arnold M. Saxton University of Tennessee - Knoxville, [email protected] Jung H. Kim Marshall University Follow this and additional works at: https://trace.tennessee.edu/utk_nutrpubs Part of the Animal Sciences Commons, and the Nutrition Commons Recommended Citation BMC Genomics 2010, 11:713 doi:10.1186/1471-2164-11-713 This Article is brought to you for free and open access by the Nutrition at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Nutrition Publications and Other Works by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact [email protected]. Stewart et al. BMC Genomics 2010, 11:713 http://www.biomedcentral.com/1471-2164/11/713 RESEARCH ARTICLE Open Access Genetic and genomic analysis of hyperlipidemia, obesity and diabetes using (C57BL/6J × TALLYHO/JngJ) F2 mice Taryn P Stewart1, Hyoung Yon Kim2, Arnold M Saxton3, Jung Han Kim1* Abstract Background: Type 2 diabetes (T2D) is the most common form of diabetes in humans and is closely associated with dyslipidemia and obesity that magnifies the mortality and morbidity related to T2D. The genetic contribution to human T2D and related metabolic disorders is evident, and mostly follows polygenic inheritance. The TALLYHO/ JngJ (TH) mice are a polygenic model for T2D characterized by obesity, hyperinsulinemia, impaired glucose uptake and tolerance, hyperlipidemia, and hyperglycemia.
    [Show full text]
  • Datasheet: VMA00346 Product Details
    Datasheet: VMA00346 Description: MOUSE ANTI AKR1C2 Specificity: AKR1C2 Format: Purified Product Type: PrecisionAb™ Monoclonal Isotype: IgG2a Quantity: 100 µl Product Details Applications This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols. Yes No Not Determined Suggested Dilution Western Blotting 1/1000 PrecisionAb antibodies have been extensively validated for the western blot application. The antibody has been validated at the suggested dilution. Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Further optimization may be required dependant on sample type. Target Species Human Product Form Purified IgG - liquid Preparation Mouse monoclonal antibody prepared by affinity chromatography on Protein G Buffer Solution Phosphate buffered saline Preservative 0.09% Sodium Azide (NaN3) Stabilisers Immunogen Recombinant human AKR1C2 External Database Links UniProt: P52895 Related reagents Entrez Gene: 1646 AKR1C2 Related reagents Synonyms DDH2 Specificity Mouse anti Human AKR1C2 antibody recognizes the aldo-keto reductase family 1 member C2, also known as 3-alpha-HSD3, DD-2, DD/BABP, aldo-keto reductase family 1 member C2, Page 1 of 2 chlordecone reductase homolog HAKRD, dihydrodiol dehydrogenase 2, bile acid binding protein, 3-alpha hydroxysteroid dehydrogenase, type III, pseudo-chlordecone reductase, testicular 17,20-desmolase deficiency, trans-1,2-dihydrobenzene-1,2-diol dehydrogenase and type II dihydrodiol dehydrogenase. Encoded by the AKR1C2 gene, aldo-keto reductase family 1 member C2 is a member of the aldo/keto reductase superfamily, which consists of more than 40 known enzymes and proteins.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]
  • Pancancer Progression Human Vjune2017
    Gene Symbol Accession Alias/Prev Symbol Official Full Name AAMP NM_001087.3 - angio-associated, migratory cell protein ABI3BP NM_015429.3 NESHBP|TARSH ABI family, member 3 (NESH) binding protein ACHE NM_000665.3 ACEE|ARACHE|N-ACHE|YT acetylcholinesterase ACTG2 NM_001615.3 ACT|ACTA3|ACTE|ACTL3|ACTSG actin, gamma 2, smooth muscle, enteric ACVR1 NM_001105.2 ACTRI|ACVR1A|ACVRLK2|ALK2|FOP|SKR1|TSRI activin A receptor, type I ACVR1C NM_145259.2 ACVRLK7|ALK7 activin A receptor, type IC ACVRL1 NM_000020.1 ACVRLK1|ALK-1|ALK1|HHT|HHT2|ORW2|SKR3|TSR-I activin A receptor type II-like 1 ADAM15 NM_207195.1 MDC15 ADAM metallopeptidase domain 15 ADAM17 NM_003183.4 ADAM18|CD156B|CSVP|NISBD|TACE ADAM metallopeptidase domain 17 ADAM28 NM_014265.4 ADAM 28|ADAM23|MDC-L|MDC-Lm|MDC-Ls|MDCL|eMDC II|eMDCII ADAM metallopeptidase domain 28 ADAM8 NM_001109.4 CD156|MS2 ADAM metallopeptidase domain 8 ADAM9 NM_001005845.1 CORD9|MCMP|MDC9|Mltng ADAM metallopeptidase domain 9 ADAMTS1 NM_006988.3 C3-C5|METH1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 ADAMTS12 NM_030955.2 PRO4389 ADAM metallopeptidase with thrombospondin type 1 motif, 12 ADAMTS8 NM_007037.4 ADAM-TS8|METH2 ADAM metallopeptidase with thrombospondin type 1 motif, 8 ADAP1 NM_006869.2 CENTA1|GCS1L|p42IP4 ArfGAP with dual PH domains 1 ADD1 NM_001119.4 ADDA adducin 1 (alpha) ADM2 NM_001253845.1 AM2|dJ579N16.4 adrenomedullin 2 ADRA2B NM_000682.4 ADRA2L1|ADRA2RL1|ADRARL1|ALPHA2BAR|alpha-2BAR adrenoceptor alpha 2B AEBP1 NM_001129.3 ACLP AE binding protein 1 AGGF1 NM_018046.3 GPATC7|GPATCH7|HSU84971|HUS84971|VG5Q
    [Show full text]
  • Targeting PH Domain Proteins for Cancer Therapy
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 12-2018 Targeting PH domain proteins for cancer therapy Zhi Tan Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Bioinformatics Commons, Medicinal Chemistry and Pharmaceutics Commons, Neoplasms Commons, and the Pharmacology Commons Recommended Citation Tan, Zhi, "Targeting PH domain proteins for cancer therapy" (2018). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 910. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/910 This Dissertation (PhD) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. TARGETING PH DOMAIN PROTEINS FOR CANCER THERAPY by Zhi Tan Approval page APPROVED: _____________________________________________ Advisory Professor, Shuxing Zhang, Ph.D. _____________________________________________
    [Show full text]
  • Datasheet: VMA00334 Product Details
    Datasheet: VMA00334 Description: MOUSE ANTI AKR1C1 Specificity: AKR1C1 Format: Purified Product Type: PrecisionAb™ Monoclonal Isotype: IgG1 Quantity: 100 µl Product Details Applications This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols. Yes No Not Determined Suggested Dilution Western Blotting 1/1000 PrecisionAb antibodies have been extensively validated for the western blot application. The antibody has been validated at the suggested dilution. Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Further optimization may be required dependant on sample type. Target Species Human Product Form Purified IgG - liquid Preparation Mouse monoclonal antibody prepared by affinity chromatography on Protein G Buffer Solution Phosphate buffered saline Preservative 0.09% Sodium Azide (NaN3) Stabilisers Immunogen Recombinant human AKR1C1 External Database Links UniProt: Q04828 Related reagents Entrez Gene: 1645 AKR1C1 Related reagents Synonyms DDH, DDH1 Specificity Mouse anti Human AKR1C1 antibody detects the aldo-keto reductase family 1 member C1, also known as 20-alpha-hydroxysteroid dehydrogenase (20-alpha-HSD), chlordecone reductase Page 1 of 2 homolog HAKRC and high-affinity hepatic bile acid-binding protein (HBAB). Encoded by the AKR1C1 gene, aldo-keto reductase family 1 member C1 is a member of the aldo/keto reductase superfamily, which consists of more than 40 known enzymes and proteins. These enzymes catalyze the conversion of aldehydes and ketones to their corresponding alcohols by utilizing NADH and/or NADPH as cofactors.
    [Show full text]
  • Identification of Differentially Expressed Genes in Human Bladder Cancer Through Genome-Wide Gene Expression Profiling
    521-531 24/7/06 18:28 Page 521 ONCOLOGY REPORTS 16: 521-531, 2006 521 Identification of differentially expressed genes in human bladder cancer through genome-wide gene expression profiling KAZUMORI KAWAKAMI1,3, HIDEKI ENOKIDA1, TOKUSHI TACHIWADA1, TAKENARI GOTANDA1, KENGO TSUNEYOSHI1, HIROYUKI KUBO1, KENRYU NISHIYAMA1, MASAKI TAKIGUCHI2, MASAYUKI NAKAGAWA1 and NAOHIKO SEKI3 1Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520; Departments of 2Biochemistry and Genetics, and 3Functional Genomics, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan Received February 15, 2006; Accepted April 27, 2006 Abstract. Large-scale gene expression profiling is an effective CKS2 gene not only as a potential biomarker for diagnosing, strategy for understanding the progression of bladder cancer but also for staging human BC. This is the first report (BC). The aim of this study was to identify genes that are demonstrating that CKS2 expression is strongly correlated expressed differently in the course of BC progression and to with the progression of human BC. establish new biomarkers for BC. Specimens from 21 patients with pathologically confirmed superficial (n=10) or Introduction invasive (n=11) BC and 4 normal bladder samples were studied; samples from 14 of the 21 BC samples were subjected Bladder cancer (BC) is among the 5 most common to microarray analysis. The validity of the microarray results malignancies worldwide, and the 2nd most common tumor of was verified by real-time RT-PCR. Of the 136 up-regulated the genitourinary tract and the 2nd most common cause of genes we detected, 21 were present in all 14 BCs examined death in patients with cancer of the urinary tract (1-7).
    [Show full text]